

# DEBASISH F. ROYCHOWDHURY, MD

President, Nirvan Consultants, LLC

79, Laconia St, Lexington, MA 02420  
Telephone: 610-772-1703; Fax: 781-652-0083  
Email: [Debasish.Roychowdhury@outlook.com](mailto:Debasish.Roychowdhury@outlook.com)  
[dfr61@yahoo.com](mailto:dfr61@yahoo.com)  
Web: [www.NirvanHealth.com](http://www.NirvanHealth.com)

---

Currently President of Nirvan Consultants, LLC and providing advice to companies, organizations, institutions and individuals in the biomedical field, including pharmaceutical and biotechnology companies academic centers and foundations. The advice ranges from overall strategy, portfolio management, business development to more tactical issues of research and development, fund raising and commercialization.

## KEY ACHIEVEMENTS:

Medical oncologist with 15+ years of comprehensive pharmaceutical industry and senior management experience and 14+ years of patient care, academic research and teaching experience. A track record of consistently achieving results through personal commitment, leadership, and a deep commitment to patients, customer focus and developing people and teams.

In the pharmaceutical industry, a career history of increasing responsibility, both strategic and tactical, across multiple functional and cross-functional areas, regions and matrices, including – all stages of R&D, regulatory, commercial operations and medical affairs, market access, business development and alliance management. Direct therapeutic area experience mostly in oncology and hematology and supportive care as well as critical care, bone disease and indirectly in other areas through functional input.

Accomplishments and experience include:

- Nine new drug approvals in US and EU and other markets (Alimta, Arranon, Tykerb, oral Hycamtin, Promacta, Votrient, Oforta, Jevtana, Zaltrap) and numerous supplemental approvals (incl. Gemzar)
- Successfully supported Halozyme as a consultant, to reverse the clinical hold on Study 202 and PEGPH20 program by FDA and DMC (March-May 2014)
- As acting CMO key team member guiding the M&A of Seragon by Roche/Genentech for \$1.725B and supported IPO efforts (July 2014)
- Supported the Aileron team for a successful submission of the IND for ALRN 6924 (FDA approval July 2014)
- Successfully established and built the fully integrated Sanofi Oncology Division as well as led the full integration of hematology/oncology and transplant businesses of Genzyme and the Sanofi Oncology Division
- Key presentations for company including to regulatory authorities, including advisory committees, investors and analysts and company board of directors
- Deep expertise in drug development
- Expertise in regulatory affairs and policy matters pertaining to drug development
- Successful launches and life cycle management of commercialized products
- Created global and cross functional teams at project and business unit level and function-based teams
- Budget management to ensure efficiency and driving growth while ensuring talent retention and organizational health and employee engagement (most current responsibilities: direct management ~650M USD operational budget and over 500 people; indirect management ~1B USD operational budget and 1500 people)
- Global perspective in health care needs and issues as well as management needs and tactics
- Participated and managed, including with decision making capacity, critical corporate committees, alliance steering committees and external working groups.
- Training, development, preceptorship and mentoring in the academic career as well as in industry
- Experience in hematology and oncology practice in academic, VA and private practice setting; provided patient care in US and India

## PROFESSIONAL EXPERIENCE:

- Ra Pharmaceuticals, Cambridge, MA – Acting CMO (September 2014-)
- OxOnc Services Company, Princeton, NJ – Advisor, Consultant and Partner (Jan 2014-)
- ProNAi Therapeutics, Inc., MI – Consultant (Jan 2015-)
- Idera Pharmaceuticals, Inc., Cambridge, MA – Advisor and Consultant (July 2014-December 2014)
- Seragon Pharmaceuticals, San Diego, CA – Acting CMO (March 2014-Aug 2014)
- Consultant to various companies (ad hoc) since Jan 2014

- Sanofi - Senior Vice President, and Head, Global Oncology Business Unit (2009-2013)
- GSK - Senior Vice President, and Head, Medicines Development, Oncology R&D Unit (2008-9)  
Medicine Development Leader, Pazopanib (2008)  
Vice President, Global Clinical Development, Oncology MDC (2005-8)  
Vice President, Oncology (Clinical), US Pharmaceuticals (2005-8)
- Eli Lilly - Director, US Regulatory Affairs (2004-2005) Oncology, Critical Care/Cardiology,  
Inflammation, Genomics/Biomarkers  
Director, US Regulatory Affairs (2002-2004) Oncology  
Senior Clinical Research Physician (2002)  
Clinical Research Physician (1999-2001)
- VA - Consultant, Staff Physician (1999-2002), VAMC, Indianapolis, IN
- Univ. of Cincinnati  
Assistant Professor in Medicine (1995-99)  
Division of Hematology/Oncology, University of Cincinnati, OH  
Adjunct Assistant Professor of Pharmaceutics (1998-)  
Division of Pharmaceutics Sciences, College of Pharmacy, University of Cincinnati  
Co-Director, Hematology/Oncology Fellowship Program (1996-99)
- VA - Staff Physician (1995-99), Veterans Administration Medical Center, Cincinnati, OH  
Associate Chief, Clinical Research, Hematology/Oncology Section (1996-99)  
VA Medical Center, Cincinnati, OH
- All India Institute of Medical Sciences, New Delhi, India – Chief Resident (Registrar), 1988
- **Postgraduate Education and Training (Internships, Residencies and Fellowship)**  
Fellow in Hematology/Oncology (1992-95) - University of California, San Francisco, CA  
Chief Resident in Internal Medicine (1991-92) - Michael Reese Hospital and Medical Center, Chicago, IL  
Resident in Internal Medicine (M.D.) (1989-91)- Michael Reese Hospital and Medical Center, Chicago, IL  
Resident, Internal Medicine (M.D.) (1985-87) - All India Institute of Medical Sciences, New Delhi, India.  
Internship (1984) - All India Institute of Medical Sciences, New Delhi, India.
- **Undergraduate Education**  
M.B.,B.S. (1979-84) - All India Institute of Medical Sciences, New Delhi, India.
- **Research Training**  
Masters in Public Health - Ohio State University, Columbus, OH (1996-98 – course not completed)  
Training in cost analysis in health care industry (July-Sept 1997) - Organization Effectiveness Unit, Health  
Alliance of Greater Cincinnati  
Train The Trainer Workshop, Cancer Genetics (June 1997) - American Society of Clinical Oncology  
Scholar in Clinical Research Training Program (1993-95) - University of California, San Francisco, CA

## COMMITTEE/BOARD MEMBERSHIP

- Member of Board of Directors, Art in Giving, Wellesley, MA (2015-)
- Member of Scientific Advisory Board, New Century Health, Wellesley, MA (2013-)
- Member of AACR Annual Meeting Clinical Trials Committee (2013-15)
- Member of Ext. Advisory Board, Levine Cancer Institute, Carolinas HealthCare System, Charlotte (2013-)
- Member of Board, Invictus Oncology, New Delhi, India (2014-)
- Member of SAC-Oncology, Dept of Biotechnology, Ministry of Science and Technology, Govt. of India (2014-)
- Member of Board of MassBio (2013-2014)
- Member of Clinical and Scientific Advisory Board, Seragon Pharmaceuticals, San Diego, CA (Mar 2014-Aug 2014)
- Member of Scientific Advisory Council, Piramal Enterprises, Ltd, Mumbai, India (Jan 2014- Sep 2014)

## PROFESSIONAL CERTIFICATIONS and LICENSURES:

- **Certification**  
Medical Oncology (American Board of Internal Medicine) - Nov. 1995  
Internal Medicine (American Board of Internal Medicine) - Sept. 1992  
Internal Medicine (All India Institute of Medical Sciences) - Dec. 1987

- **Licensures**

Indiana State Medical Board (June 1999-2005) - inactive  
Ohio State Medical Board (Feb. 1995-2000) - inactive  
California State Medical Board (May 1992-2000) - inactive  
Drug Enforcement Agency (May 1992-1999) - inactive  
Medical Council of India (1985-) - active

**PROFESSIONAL TRAINING AND DEVELOPMENT**

Executive Development Program (2006) - Wharton School of Business, U. Penn, Philadelphia  
Enhancing Executive Influence (2004) - Harvard Business School, MA  
Business Leadership Training Programs (2000, 2002, 2004) - Eli Lilly and Company  
Emerging Leader Training Program (1999) - Columbia University, New York

**PROFESSIONAL ASSOCIATION MEMBERSHIPS**

American Association of Cancer Research  
American Society of Clinical Oncologists  
European Society of Medical Oncology  
Regulatory Affairs Professional Society  
Drug Information Association  
Indian Medical Association

**LIST OF PUBLICATIONS, INVITED PRESENTATIONS AND REFERENCES:**

Provided upon request.